Natera Seeks PMDA Approval for Signatera in Muscle-Invasive Bladder Cancer — Natera, Inc.

Event summary

Natera submitted Signatera™ to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer (MIBC).
The submission follows Signatera's June 2026 PMDA approval in colorectal cancer, making it Japan’s first approved molecular residual disease (MRD) test.
The application is supported by data from the IMvigor011 Phase 3 clinical trial and recent U.S. FDA approval for adjuvant atezolizumab (Tecentriq®).
Bladder cancer affects over 34,000 people annually in Japan, with 20–25% of cases being muscle-invasive.

The big picture

Natera’s submission for Signatera in MIBC underscores its strategic push into Japan’s precision oncology market. The move follows its first PMDA approval in colorectal cancer, positioning the company to capitalize on growing demand for molecular residual disease (MRD) testing. With bladder cancer representing a significant unmet need in Japan, Natera aims to leverage its existing regulatory and clinical milestones to drive adoption.

What we're watching

Regulatory Momentum: Whether Natera can secure PMDA approval for Signatera in MIBC, following its success in colorectal cancer.
Market Expansion: The pace at which Natera expands its presence in Japan’s oncology diagnostics market.
Clinical Validation: How the IMvigor011 trial data influences broader adoption of Signatera as a companion diagnostic globally.